Search

Your search keyword '"A. G. Turkina"' showing total 59 results

Search Constraints

Start Over You searched for: Author "A. G. Turkina" Remove constraint Author: "A. G. Turkina" Journal blood Remove constraint Journal: blood
59 results on '"A. G. Turkina"'

Search Results

1. Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

2. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

3. The 15 Year Long-Term Survival of Patients with Chronic Myeloid Leukaemia from 35 Regions of Russian Federation: A Follow up of a Multicenter Observation Study Eutos Osp Initiated By European Leukemia NET

4. Humoral Immunity and Adverse Events after Vaccination Against COVID-19 By a Vector Based Vaccine Sputnik V in Patients with Chronic Myeloid Leukemia

5. Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

6. Results of a Single Center Survey on Vaccination Against COVID-19 in Patients with Chronic Myeloid Leukemia

7. The First Results of Asciminib Therapy in Highly Pretreated Chronic Myeloid Leukemia Patients Under the Managed Access Program (MAP) in Russian Federation

8. PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1T315I

9. ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia

10. The Role of BCR-ABL Levels Fluctuations and Loss of Deep Molecular Response after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia in the Prospective Trial RU-SKI

11. Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

12. On a Long Way to the Treatment Free Remisson: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study

13. The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

14. Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

15. PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I

16. Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment

17. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

18. Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

19. Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

20. Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

21. Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up

22. Analysis of the Effectiveness of Maintenance Therapy By Imatinib in Patients with Pdgfra-Positive Neoplasm

23. Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update

24. PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

25. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

26. Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

27. Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML

28. Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

29. Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop

30. Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission

31. The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia

32. Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

33. Introduction of a Treatment Approach for Chronic Myeloid Leukemia and Pregnancy Considering Leukemic Burden and Pregnancy Terms

34. The Rate of Individual BCR-ABL Decline As an Optimized Predictor of Tyrosine Kinase Inhibitors Treatment Outcome in Chronic Phase CML Patients, Comparison with CML Prognostic Scores and Early Molecular Response Achievement

35. Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure

36. Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

37. Russian Registry of Chronic Myeloid Leukemia Management in Routine Clinical Practice-Local Therapy and Monitoring

38. Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials

39. Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

40. Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

41. Prognostic Value of the Rate of BCR-ABL Decline for Patients with Chronic Myelogenous Leukemia in Chronic Phase on Tyrosine Kinase Inhibitors Treatment

42. Polymorphism of UGT1A1 and Frequency of Hyperbilirubinemia in Patients with Chronic Myeloid Leukemia Treated By Nilotinib

43. Challenge to Use the Interval Censorship Estimators for Time to Response Evaluation By Data from Chronic Myeloid Leukemia Registry

44. Long-Term Results and Adverse Events Of Second Line Nilotinib Therapy After Imatinib Failure In Patients With Chronic Myeloid Leukemia In Chronic Phase In Clinical Practice

45. ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

46. Is Superinstability Of Karyotype Of Acute Myeloid Leukemia 'Relic Radiation From Big Bang' Of Chromosome Homeostasis On MDS Stage?

47. First Results of Russian Multicenter Population Base Study of the Incidence of Chronic Myeloid Leukemia

48. Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

49. Results of Tyrosine Kinase Inhibitors (TKI) Therapy of Patients (Pts) with Chronic Myeloid Leukemia (CML) In Clinical Practice Analysed In the Frame of International Research Project EUTOS In Russian Federation

50. Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd

Catalog

Books, media, physical & digital resources